Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $42.00

Bicara Therapeutics (NASDAQ:BCAX) had its target price hoisted by HC Wainwright from $40.00 to $42.00 in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Bicara Therapeutics’ Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($2.56) EPS.

Several other research analysts also recently issued reports on the stock. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Citizens Jmp initiated coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued a “market perform” rating and a $31.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, January 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Finally, Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.00.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $21.47 on Tuesday. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -8.49 and a beta of -1.23. The stock has a fifty day moving average price of $17.36 and a two-hundred day moving average price of $16.73. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $21.50.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, March 30th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.04. As a group, research analysts predict that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Insider Buying and Selling at Bicara Therapeutics

In related news, CEO Claire Mazumdar sold 36,766 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,506,144.64. The trade was a 9.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Ryan Cohlhepp sold 17,392 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $18.16, for a total transaction of $315,838.72. Following the completion of the transaction, the chief operating officer owned 205,141 shares in the company, valued at $3,725,360.56. This represents a 7.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 137,969 shares of company stock valued at $2,586,198. 15.50% of the stock is currently owned by company insiders.

Institutional Trading of Bicara Therapeutics

Institutional investors have recently bought and sold shares of the business. Deutsche Bank AG raised its position in shares of Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock valued at $2,165,000 after acquiring an additional 1,171 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares during the last quarter. Mariner LLC grew its stake in shares of Bicara Therapeutics by 3.0% during the fourth quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after purchasing an additional 1,902 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Bicara Therapeutics by 13.2% during the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after purchasing an additional 1,962 shares during the period.

Bicara Therapeutics News Summary

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 quarterly and full‑year EPS forecasts (Q1–Q4 and FY2026) and reiterated a “Buy” rating with a $42 price target — the firm trimmed expected losses for each quarter and the year, signaling improved analyst confidence. Read More.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on BCAX, adding third‑party validation from another biopharma‑focused shop that can boost investor sentiment. Read More.
• Positive Sentiment: Goldman Sachs published bullish commentary indicating expected upside for BCAX, which helps drive demand from institutional and retail investors watching analyst cues. Read More.
• Positive Sentiment: Wells Fargo highlighted strong price‑appreciation potential for Bicara, contributing additional buy‑side momentum. Read More.
• Positive Sentiment: Aggregate Wall Street price targets (per Zacks) imply roughly ~55% upside from current levels — the headline can attract momentum traders and investors seeking high‑growth biotechs. Read More.
• Neutral Sentiment: Recent Q4 2025 results showed a slight beat to loss estimates (EPS better than consensus by $0.04), but the company remains unprofitable with consensus FY2026 EPS still a negative figure — investors are reacting to rate of improvement, not profitability yet. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.